Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,647 stopped studies mapped to Malignant Lung Neoplasm and descendants · 90% state a reason
Over the 1,647 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04274907 | A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult… | Phase 1 | terminated | Feb 18, 2020 | AbbVie | Company Decision | Sponsor / business decision |
| NCT02400424 | Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor(GFPC_01-14) | N/A | terminated | Mar 27, 2015 | Centre Leon Berard | Approval of adjuvant durvalumab after RT-CT (not anticipated in the study design) and small number… | Other (stated, no rule matched) |
| NCT03256721 | Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment… | Phase 2 | terminated | Aug 22, 2017 | Fuzhou General Hospital | Due to the enrollment was slow and exceeded the expected enrollment time | Enrollment / accrual |
| NCT04267237 | A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus… | Phase 2 | withdrawn | Feb 12, 2020 | Hoffmann-La Roche | Accrual timelines | Enrollment / accrual |
| NCT02893332 | Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung…(Sindas) | Phase 3 | terminated | Sep 8, 2016 | Sichuan Provincial People's Hospital | After interim analysis, IRB recommend termination. | Efficacy / futility |
| NCT03500393 | A Remotely Supervised Exercise Program for Lung Cancer Patients Undergoing Chemoradiation… | N/A | terminated | Apr 18, 2018 | Dartmouth-Hitchcock Medical Center | feasibility of study recruitment | Enrollment / accrual |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth… | Phase 1 | terminated | Apr 24, 2017 | ADC Therapeutics S.A. | Safety | Safety / toxicity |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons. | Safety / toxicity |
| NCT03901378 | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade… | Phase 2 | withdrawn | Apr 3, 2019 | Ochsner Health System | Lack of accrual | Enrollment / accrual |
| NCT02262000 | Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer(SABR) | N/A | terminated | Oct 10, 2014 | West Virginia University | Investigator left institution | Investigator |
| NCT02485652 | Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive… | Phase 2 | terminated | Jun 30, 2015 | Hanmi Pharmaceutical Company Limited | Study termination by the Sponsor | Other (stated, no rule matched) |
| NCT03382899 | Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone…(Cypress 1) | Phase 2 | terminated | Dec 26, 2017 | Eli Lilly and Company | The CYPRESS-1 trial was closed early after the planned primary analysis because the risk benefit… | Other (stated, no rule matched) |
| NCT04170959 | The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC(RADFORMIN) | Phase 2 | terminated | Nov 20, 2019 | ethisch.comite@uza.be | Loss of external funding | Funding |
| NCT00760929 | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on… | Phase 2 | terminated | Sep 26, 2008 | Hoffmann-La Roche | The study was terminated due to the termination of the clinical development program. | Other (stated, no rule matched) |
| NCT00662597 | ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment…(ATRACT-1) | Phase 3 | terminated | Apr 21, 2008 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00738387 | A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for…(ATTRACT-2) | Phase 3 | terminated | Aug 20, 2008 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01268059 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced… | Phase 1 / Phase 2 | terminated | Dec 29, 2010 | MedImmune LLC | In conjunction with the overall risk-benefit assessment, study was terminated prematurely due to… | Safety / toxicity |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients… | Phase 3 | terminated | May 30, 2007 | GlaxoSmithKline | The study was terminated following assessment of the lack of efficacy of the study product by the… | Efficacy / futility |
| NCT03516084 | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based… | Phase 3 | terminated | May 4, 2018 | Zai Lab (Shanghai) Co., Ltd. | As the treatment model of extensive-stage small cell lung cancer changed rapidly and the enrollment… | Enrollment / accrual |
| NCT03603652 | NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of… | N/A | terminated | Jul 27, 2018 | Ethicon, Inc. | Study originally suspended pending a protocol amendment but study now terminated. | Other (stated, no rule matched) |
| NCT03246854 | A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer | Phase 1 | terminated | Aug 11, 2017 | National Health Research Institutes, Taiwan | No more funding | Funding |
| NCT04576208 | A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related… | Phase 2 | withdrawn | Oct 6, 2020 | Takeda | Business Decision (no safety or efficacy concerns) | Safety / toxicity |
| NCT00003492 | Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT00794417 | A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in… | Phase 1 / Phase 2 | terminated | Nov 20, 2008 | Regeneron Pharmaceuticals | not stated | Not stated |
| NCT04460729 | A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14… | Phase 2 | withdrawn | Jul 8, 2020 | Novartis Pharmaceuticals | company decision | Sponsor / business decision |
| NCT00269828 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received…(PIONEER) | Phase 3 | terminated | Dec 26, 2005 | CTI BioPharma | not stated | Not stated |
| NCT00601848 | Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That… | Phase 2 | terminated | Jan 28, 2008 | Abramson Cancer Center at Penn Medicine | Poor accrual and change in standards of care | Enrollment / accrual |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC…(N3) | Phase 1 / Phase 2 | withdrawn | Dec 4, 2017 | Royal Marsden NHS Foundation Trust | Withdrawal of financial support from funder | Funding |
| NCT04267913 | Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care… | Phase 2 | withdrawn | Feb 13, 2020 | SWOG Cancer Research Network | The pharmaceutical company sold the compound and pulled out. | Sponsor / business decision |
| NCT03553550 | Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected…(LIBERTI) | — | terminated | Jun 12, 2018 | Addario Lung Cancer Medical Institute | Enrollment futility | Efficacy / futility |
| NCT02762877 | Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma… | — | terminated | May 5, 2016 | Genomic Health®, Inc. | Business decision | Sponsor / business decision |
| NCT04044170 | Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | Phase 2 | terminated | Aug 5, 2019 | Hanmi Pharmaceutical Company Limited | Study termination by the Sponsor | Other (stated, no rule matched) |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer…(DOMINATION) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT04262388 | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab…(DOME) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT02109653 | Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant… | Phase 2 | withdrawn | Apr 10, 2014 | Array Biopharma, now a wholly owned subsidiary of Pfizer | Study never started - transferred to Array. | Other (stated, no rule matched) |
| NCT00538681 | Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer… | Phase 2 | terminated | Oct 3, 2007 | Eli Lilly and Company | Terminated due to lack of efficacy demonstrated in relevant participant population in other… | Efficacy / futility |
| NCT03699033 | Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung… | Phase 2 | withdrawn | Oct 9, 2018 | Stephanie Smiddy | No patients available | Other (stated, no rule matched) |
| NCT04610606 | Pilot Prehabilitation Intervention in Lung Cancer | N/A | terminated | Oct 30, 2020 | McGill University | Covid-19 pandemic | COVID-19 / pandemic |
| NCT03302247 | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | Phase 2 | terminated | Oct 5, 2017 | Fox Chase Cancer Center | Unable to accrue subjects | Enrollment / accrual |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin…(NeoFIND) | Phase 2 | terminated | Oct 30, 2018 | Advanced Accelerator Applications | Recruitment was stopped before the target sample size was achieved. | Enrollment / accrual |
| NCT02318368 | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects…(FOCAL) | Phase 2 | terminated | Dec 17, 2014 | AVEO Pharmaceuticals, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT00576225 | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL | Phase 3 | withdrawn | Dec 19, 2007 | CTI BioPharma | not stated | Not stated |
| NCT01188707 | A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung… | Phase 1 / Phase 2 | terminated | Aug 25, 2010 | Herlev Hospital | Dose over MTD reached | Other (stated, no rule matched) |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT02642939 | Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic… | Phase 2 | terminated | Dec 30, 2015 | Check, Jerome H., M.D., Ph.D. | Lack of enrollment | Enrollment / accrual |
| NCT03501056 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced… | Phase 2 | withdrawn | Apr 18, 2018 | Fuda Cancer Hospital, Guangzhou | No participants enrolled | Enrollment / accrual |
| NCT03945227 | Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus… | Phase 2 | withdrawn | May 10, 2019 | Yonsei University | Due to the delay in the study shceduled, due to the start of competitive study and the approval of… | Safety / toxicity |
| NCT00054184 | Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive… | Phase 3 | terminated | Feb 6, 2003 | CTI BioPharma | not stated | Not stated |
| NCT00054197 | Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients… | Phase 3 | terminated | Feb 6, 2003 | CTI BioPharma | not stated | Not stated |
| NCT00054210 | Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in… | Phase 3 | terminated | Feb 6, 2003 | CTI BioPharma | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Feb 11, 2021source: clinicaltrials